文献速递前列腺癌

挽救性不可逆电穿孔治疗放疗后复发性前列腺癌:前瞻性FIRE试验

Salvage irreversible electroporation for radio-recurrent prostate cancer - the prospective FIRE trial.
PubMed 文献 · BJU Int · 2023-01-09

FIRE试验为多中心前瞻性研究,纳入37例放疗后局部复发性前列腺癌患者,评估挽救性不可逆电穿孔(IRE)的安全性、功能与肿瘤学结局。中位随访29个月,19%患者出现3级不良事件(尿道碎屑需经尿道切除),12个月时93%患者保持控尿,勃起功能充足率从35%降至15%,局部控制率78%,73%无局部及全身疾病,16%出现转移。作者认为挽救性IRE安全性好、毒性轻微,功能与肿瘤学结局有前景。

要点

  • 37例放疗后局部复发性前列腺癌患者接受挽救性IRE,中位随访29个月。
  • 19%患者出现3级不良事件,为尿道碎屑需经尿道切除。
  • 12个月局部控制率78%,73%无局部及全身疾病,16%出现转移。

核心结论

  • FIRE试验显示,放疗失败后局部前列腺癌的挽救性IRE安全性好、毒性轻微,功能和肿瘤学结局有前景,可为难以管理的放疗后复发性前列腺肿瘤提供可能的解决方案。

研究设计与样本

  • 多中心前瞻性试验,纳入外照射放疗或近距离放疗后局部复发性前列腺癌、分期影像无转移且mpMRI与活检共定位的男性患者,分析37例。

主要发现

  • 7例(19%)报告自限性尿急、尿频或血尿(1-2级),7例(19%)发生3级不良事件(尿道碎屑需经尿道切除)。
  • 治疗后12个月93%患者保持控尿,勃起功能足以性交者从35%降至15%(4/27)。
  • 29例(78%)获得局部控制,27例(73%)无局部及全身疾病,4例(11%)仅局部复发。
  • 6例(16%)出现转移,中位转移时间8个月。

关键数值与推荐

  • 局部复发定义为活检任何ISUP评分≥2。
  • 随访包括每3个月PSA、6个月mpMRI及12个月标准化经会阴模板定位活检,此后以MRI和/或PSMA-PET/CT及PSA指导随访。
  • 中位年龄71岁(53-83),中位PSA 3.5 ng/mL(2.7-6.1),28例(75.5%)为中危、9例(24.5%)为高危前列腺癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To prospectively assess the safety, functional- and oncological-outcomes of irreversible electroporation (IRE) as salvage therapy for radio-recurrent focal prostate cancer in a multicenter setting. PATIENTS AND METHODS: Men with focal recurrent PCa after external beam radiation or brachytherapy without metastatic disease on staging imaging and co-registration between mpMRI and biopsies were prospectively included in this multicenter trial. Adverse events were reported following the Clavien-Dindo classification. Validated questionnaires were used for patient-reported functional outcomes. Follow-up consisted of 3 monthly prostate specific antigen (PSA) levels, a 6-month mpMRI and standardised transperineal template mapping biopsies at 12-months. Thereafter follow-up was guided by MRI and/or PSMA-PET/CT and PSA. Local recurrence was defined as any ISUP score ≥2 on biopsies. RESULTS: 37 patients were analysed with a median (interquartile range (IQR)) follow up of 29 (22-43) months. Median age was 71 (53-83), median PSA was 3.5 ng/mL (2.7-6.1). 28 (75.5%) patients harboured intermediate risk and 9 patients (24.5%) high risk PCa. Seven patients (19%) reported self-limiting urgency, frequency, or hematuria (grade 1-2). Seven patients (19%) developed a grade 3 AE; urethral sludge requiring transurethral resection. At 12 months post treatment 93% of patients remained continent and erectile function sufficient for intercourse deteriorated from 35% to 15% (4/27). Local control was achieved in 29 patients (78%) and 27 patients (73%) were clear of local and systemic disease. Four (11%) patients had local recurrence only. Six (16%) patients developed metastatic disease with a median time to metastasis of 8 months. CONCLUSION: The FIRE trial shows that salvage IRE after failed radiation therapy for localised PCa is safe with minimal toxicity, and promising functional and oncological outcomes. Salvage IRE can offer a possible solution for notoriously difficult to manage radio recurrent prostate tumours.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Blazevski A, Geboers B, Scheltema MJ, et al. Salvage irreversible electroporation for radio-recurrent prostate cancer - the prospective FIRE trial. BJU Int. 2023. PMID: 36495482. doi:10.1111/bju.15947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。